A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers
- 1 March 2005
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 21 (5) , 575-582
- https://doi.org/10.1111/j.1365-2036.2005.02381.x
Abstract
Tenatoprazole is a novel proton pump inhibitor with a seven-hour plasma half-life. To compare the effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric acidity during the first 48 h in healthy volunteers. This randomized two-period crossover study included 24 Helicobacter Pylori-negative subjects; tenatoprazole 40 mg or esomeprazole 40 mg daily were given before breakfast for two consecutive days, with a 2-week wash-out between the administration periods. Intragastric pH was monitored for 48 h. Over 48 h, tenatoprazole 40 mg exerted a more potent acid inhibition than esomeprazole 40 mg (median pH: 4.3 vs. 3.9, P < 0.08; per cent of time above pH 4: 57% vs. 49%, P < 0.03; proportion of subjects with at least half of the time above pH 4: 71% vs. 46%). These differences resulted from better night-time acid control with tenatoprazole 40 mg than esomeprazole 40 mg (first night median pH: 4.2 vs. 2.9, P < 0.0001; second night: 4.5 vs. 3.2, P < 0.0001). The duration of nocturnal acid breakthroughs was significantly reduced during both nights. In contrast, no significant difference was detected during the daytime periods between both regimens. Over the first 48 h, tenatoprazole 40 mg achieves a better overall and night-time control of gastric pH than esomeprazole 40 mg. The translation of better early control of acidity into clinical benefits deserves further studies.Keywords
This publication has 29 references indexed in Scilit:
- Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthroughAlimentary Pharmacology & Therapeutics, 2004
- Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half‐life: effects on intragastric pH and comparison with esomeprazole in healthy volunteersAlimentary Pharmacology & Therapeutics, 2004
- Pharmacokinetics of tenatoprazole, a novel proton pump inhibitor, in healthy male Caucasian volunteersGastroenterology, 2003
- Gastroduodenal posters 227-241Gut, 2002
- Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mgGastroenterology, 2000
- Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mgGastroenterology, 2000
- Rapid Effect of Lansoprazole on Intragastric pH: a Crossover Comparison with OmeprazoleScandinavian Journal of Gastroenterology, 1999
- A placebo‐controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24‐h intragastric acidity and plasma gastrin concentrations in young healthy male subjectsAlimentary Pharmacology & Therapeutics, 1998
- Proton Pump InhibitorsDrugs, 1998
- Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis.Gut, 1996